Abstract
We have previously described enhanced human breast cancer cell proliferation and mouse mammary tumor growth induced by α2-adrenergic agonists, associated with α2-adrenoceptor (α2-AR) expression in epithelial cells. The aim of the present work was to assess if stromal fibroblasts can contribute to this effect. α2-AR expression was assessed by immunocytochemistry and immunohistochemistry, cell proliferation by [3H]- Thymidine incorporation and tumor growth by measuring with caliper. All tested mouse and human fibroblasts expressed at least two α2-AR subtypes and α2-adrenergic agonists enhanced fibroblast proliferation. In vivo, the α2-adrenergic agonist clonidine significantly enhanced tumor growth. The α2- adrenergic antagonist rauwolscine reversed this effect, but when administered alone, significantly inhibited tumor growth. Clonidine significantly stimulated cell proliferation in the epithelial-enriched fraction, the cancer associated fibroblastenriched fraction and the co-culture of both fractions in primary cultures from both tumors (IBH-4 and IBH-6). Rauwolscine reversed clonidine stimulation in every fraction. However, when incubated alone, the inhibitory effect was observed in fractions from IBH-4 tumors but not from IBH-6 tumors. These experiments show that fibroblasts from tumor stroma are also influenced by α2-adrenergic compounds through the α2-ARs expressed in these cells. Moreover, the α2-adrenergic antagonist rauwolscine could eventually block in both epithelial and stromal cells, the mitogenic effect of catecholamines released during stress, providing a potential additional treatment for breast cancer patients. Chemists synthesizing adrenergic compounds should consider their action in breast cancer patients.
Keywords: Clonidine, rauwolscine, adrenoceptors, mammary tumor, carcinoma-associated fibroblasts, breast cancer, fibroblast MC4-L4F, Dexmedetomidine, G protein coupled receptors, Dulbecco's modified Eagle's medium
Current Cancer Drug Targets
Title: α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells
Volume: 11 Issue: 6
Author(s): A. Bruzzone, C. Perez Pinero, P. Rojas, M. Romanato, H. Gass, C. Lanari and I. A. Luthy
Affiliation:
Keywords: Clonidine, rauwolscine, adrenoceptors, mammary tumor, carcinoma-associated fibroblasts, breast cancer, fibroblast MC4-L4F, Dexmedetomidine, G protein coupled receptors, Dulbecco's modified Eagle's medium
Abstract: We have previously described enhanced human breast cancer cell proliferation and mouse mammary tumor growth induced by α2-adrenergic agonists, associated with α2-adrenoceptor (α2-AR) expression in epithelial cells. The aim of the present work was to assess if stromal fibroblasts can contribute to this effect. α2-AR expression was assessed by immunocytochemistry and immunohistochemistry, cell proliferation by [3H]- Thymidine incorporation and tumor growth by measuring with caliper. All tested mouse and human fibroblasts expressed at least two α2-AR subtypes and α2-adrenergic agonists enhanced fibroblast proliferation. In vivo, the α2-adrenergic agonist clonidine significantly enhanced tumor growth. The α2- adrenergic antagonist rauwolscine reversed this effect, but when administered alone, significantly inhibited tumor growth. Clonidine significantly stimulated cell proliferation in the epithelial-enriched fraction, the cancer associated fibroblastenriched fraction and the co-culture of both fractions in primary cultures from both tumors (IBH-4 and IBH-6). Rauwolscine reversed clonidine stimulation in every fraction. However, when incubated alone, the inhibitory effect was observed in fractions from IBH-4 tumors but not from IBH-6 tumors. These experiments show that fibroblasts from tumor stroma are also influenced by α2-adrenergic compounds through the α2-ARs expressed in these cells. Moreover, the α2-adrenergic antagonist rauwolscine could eventually block in both epithelial and stromal cells, the mitogenic effect of catecholamines released during stress, providing a potential additional treatment for breast cancer patients. Chemists synthesizing adrenergic compounds should consider their action in breast cancer patients.
Export Options
About this article
Cite this article as:
Bruzzone A., Perez Pinero C., Rojas P., Romanato M., Gass H., Lanari C. and A. Luthy I., α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells, Current Cancer Drug Targets 2011; 11 (6) . https://dx.doi.org/10.2174/156800911796191051
DOI https://dx.doi.org/10.2174/156800911796191051 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Current Pharmaceutical Design Defensins and Other Biocidal Proteins from Bean Seeds with Medicinal Activities
Current Medicinal Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Serum of Blood Separation by Means of Dynamic Electrochromatography in a Centrifugal and Electromagnetic Gradient
Recent Patents on Biotechnology Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Estrone Specific Molecularly Imprinted Polymeric Nanospheres: Synthesis, Characterization and Applications for Electrochemical Sensor Development
Combinatorial Chemistry & High Throughput Screening Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Multiplexed Fluorescence Imaging of Tumor Biomarkers in Gene Expression and Protein Levels for Personalized and Predictive Medicine
Current Molecular Medicine Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Steroid Receptor Ligands for Breast Cancer Targeting: An Insight into Their Potential Role As Pet Imaging Agents
Current Medicinal Chemistry Application of Bacterial Nanocellulose in Cancer Drug Delivery: A Review
Current Pharmaceutical Design Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Vitamin-D Receptor (VDR) Gene Polymorphisms (TaqI, FokI) in Turkish Patients with Hashimoto’s Thyroiditis: Relationship to the Levels of Vit-D and Cytokines
Endocrine, Metabolic & Immune Disorders - Drug Targets